Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility.

Theodorou V, Stark R, Menon S, Carroll JS.

Genome Res. 2013 Jan;23(1):12-22. doi: 10.1101/gr.139469.112. Epub 2012 Nov 21.

2.

Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover.

Adomas AB, Grimm SA, Malone C, Takaku M, Sims JK, Wade PA.

BMC Cancer. 2014 Apr 22;14:278. doi: 10.1186/1471-2407-14-278.

3.

Establishment of active chromatin structure at enhancer elements by mixed-lineage leukemia 1 to initiate estrogen-dependent gene expression.

Jeong KW, Andreu-Vieyra C, You JS, Jones PA, Stallcup MR.

Nucleic Acids Res. 2014 Feb;42(4):2245-56. doi: 10.1093/nar/gkt1236. Epub 2013 Nov 27.

4.

Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state.

Kong SL, Li G, Loh SL, Sung WK, Liu ET.

Mol Syst Biol. 2011 Aug 30;7:526. doi: 10.1038/msb.2011.59.

5.

FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M.

Cell. 2008 Mar 21;132(6):958-70. doi: 10.1016/j.cell.2008.01.018.

6.

The proteasome inhibitor bortezomib induces an inhibitory chromatin environment at a distal enhancer of the estrogen receptor-α gene.

Powers GL, Rajbhandari P, Solodin NM, Bickford B, Alarid ET.

PLoS One. 2013 Dec 5;8(12):e81110. doi: 10.1371/journal.pone.0081110. eCollection 2013.

7.

Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer.

Dreijerink KMA, Groner AC, Vos ESM, Font-Tello A, Gu L, Chi D, Reyes J, Cook J, Lim E, Lin CY, de Laat W, Rao PK, Long HW, Brown M.

Cell Rep. 2017 Mar 7;18(10):2359-2372. doi: 10.1016/j.celrep.2017.02.025.

8.

Absent, small or homeotic 2-like protein (ASH2L) enhances the transcription of the estrogen receptor α gene through GATA-binding protein 3 (GATA3).

Qi J, Huo L, Zhu YT, Zhu YJ.

J Biol Chem. 2014 Nov 7;289(45):31373-81. doi: 10.1074/jbc.M114.579839. Epub 2014 Sep 25.

9.
10.

Steroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer.

Stine ZE, McGaughey DM, Bessling SL, Li S, McCallion AS.

Hum Mol Genet. 2011 Oct 1;20(19):3746-56. doi: 10.1093/hmg/ddr291. Epub 2011 Jul 7.

11.

Enhancer activation requires trans-recruitment of a mega transcription factor complex.

Liu Z, Merkurjev D, Yang F, Li W, Oh S, Friedman MJ, Song X, Zhang F, Ma Q, Ohgi KA, Krones A, Rosenfeld MG.

Cell. 2014 Oct 9;159(2):358-73. doi: 10.1016/j.cell.2014.08.027.

12.

From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response.

Laganière J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguère V.

Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11651-6. Epub 2005 Aug 8.

13.

Differential DNase I hypersensitivity reveals factor-dependent chromatin dynamics.

He HH, Meyer CA, Chen MW, Jordan VC, Brown M, Liu XS.

Genome Res. 2012 Jun;22(6):1015-25. doi: 10.1101/gr.133280.111. Epub 2012 Apr 16.

14.

Indole-3-carbinol triggers aryl hydrocarbon receptor-dependent estrogen receptor (ER)alpha protein degradation in breast cancer cells disrupting an ERalpha-GATA3 transcriptional cross-regulatory loop.

Marconett CN, Sundar SN, Poindexter KM, Stueve TR, Bjeldanes LF, Firestone GL.

Mol Biol Cell. 2010 Apr 1;21(7):1166-77. doi: 10.1091/mbc.E09-08-0689. Epub 2010 Feb 3.

15.

Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer.

Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M.

Cancer Res. 2007 Jul 1;67(13):6477-83.

16.

Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.

Frietze S, O'Geen H, Littlepage LE, Simion C, Sweeney CA, Farnham PJ, Krig SR.

BMC Genomics. 2014 Jun 24;15:520. doi: 10.1186/1471-2164-15-520.

17.

Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells.

Holmes KA, Hurtado A, Brown GD, Launchbury R, Ross-Innes CS, Hadfield J, Odom DT, Carroll JS.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2748-53. doi: 10.1073/pnas.1018863108. Epub 2011 May 2.

18.

Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.

Hosoda M, Yamamoto M, Nakano K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H.

Breast Cancer Res Treat. 2014 Apr;144(2):249-61. doi: 10.1007/s10549-014-2867-0. Epub 2014 Feb 19.

PMID:
24549642
19.

Cell type-specific binding patterns reveal that TCF7L2 can be tethered to the genome by association with GATA3.

Frietze S, Wang R, Yao L, Tak YG, Ye Z, Gaddis M, Witt H, Farnham PJ, Jin VX.

Genome Biol. 2012 Sep 26;13(9):R52. doi: 10.1186/gb-2012-13-9-r52.

20.

Estrogen induces repression of the breast cancer and salivary gland expression gene in an estrogen receptor alpha-dependent manner.

Bretschneider N, Brand H, Miller N, Lowery AJ, Kerin MJ, Gannon F, Denger S.

Cancer Res. 2008 Jan 1;68(1):106-14. doi: 10.1158/0008-5472.CAN-07-5647.

Supplemental Content

Support Center